A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases

NCT02941744 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Stage IIIC Skin Melanoma
Stage IV Skin Melanoma

Interventions

DRUG: nivolumab
DRUG: ipilimumab

Sponsor

Universitair Ziekenhuis Brussel